|
1
|
Valero V, Holmes FA, Walters RS, Theriault
RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU and
Hortobagyi GN: Phase II trial of docetaxel: A new, highly effective
antineoplastic agent in the management of patients with
anthracycline-resistant metastatic breast cancer. J Clin Oncol.
13:2886–2894. 1995.PubMed/NCBI
|
|
2
|
Pronk LC, Stoter G and Verweij J:
Docetaxel (Taxotere): Single agent activity, development of
combination treatment and reducing side-effects. Cancer Treat Rev.
21:463–478. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hortobagyi GN and Kris MG: Expanding
horizons: An update on the use of docetaxel in non-small cell lung,
ovarian, and breast cancer. Semin Oncol. 29(3): Suppl 12. S1–S3.
2002. View Article : Google Scholar
|
|
4
|
Hennenfent KL and Govindan R: Novel
formulations of taxanes: A review. Old winein a new bottle? Ann
Oncol. 17:735–749. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Masini E, Planchenault J, Pezziardi F,
Gautier P and Gagnol JP: Histamine-releasing properties of
Polysorbate 80 in vitro and in vivo: Correlation with its
hypotensive action in the dog. Agents Actions. 16:470–477. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loos WJ, Baker SD, Verweij J, Boonstra JG
and Sparreboom A: Clinical pharmacokinetics of unbound docetaxel:
Role of polysorbate 80 and serum proteins. Clin Pharmacol Ther.
74:364–371. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tije AJ, Verweij J, Loos WJ and Sparreboom
A: Pharmacological effects of formulation vehicles: Implications
for cancer chemotherapy. Clin Pharmacokinet. 42:665–685. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esmaeili F, Dinarvand R, Ghahremani MH,
Amini M, Rouhani H, Sepehri N, Ostad SN and Atyabi F:
Docetaxel-albumin conjugates: Preparation, in vitro evaluation and
biodistribution studies. J Pharm Sci. 98:2718–2730. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Feng SS, Mei L, Anitha P, Gan CW and Zhou
W: Poly (lactide)-vitamin E derivative/montmorillonite nanoparticle
formulations for the oral delivery of docetaxel. Biomaterials.
30:3297–3306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sheikh S, Ali SM, Ahmad MU, Ahmad A,
Mushtaq M, Paithankar M, Mandal J, Saptarishi D, Sehgal A,
Maheshwari K and Ahmad I: Nanosomal Amphotericin B is an
efficacious alternative to Ambisome for fungal therapy. Int J
Pharm. 397:103–108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ali SM, Ahmad A, Sheikh S, Ahmad MU, Rane
RC, Kale P, Paithankar M, Saptarishi D, Sehgal A, Maheshwari K and
Ahmad I: Polyoxyl 60 hydrogenated castor oil free nanosomal
formulation of immunosuppressant Tacrolimus: Pharmacokinetics,
safety, and tolerability in rodents and humans. Int
Immunopharmacol. 10:325–330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hwang HY, Kim IS, Kwon IC and Kim YH:
Tumor targetability and antitumor effect of docetaxel-loaded
hydrophobically modified glycol chitosan nanoparticles. J Control
Release. 128:23–31. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu B, Yang M, Li R, Ding Y, Qian X, Yu L
and Jiang X: The antitumor effect of novel docetaxel-loaded
thermosensitive micelles. Eur J Pharm Biopharm. 69:527–534. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Du W, Hong L, Yao T, Yang X, He Q, Yang B
and Hu Y: Synthesis and evaluation of water-soluble docetaxel
prodrugs-docetaxel esters of malic acid. Bioorg Med Chem.
15:6323–6330. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
De Jong WH and Borm PJ: Drug delivery and
nanoparticles: Applications and hazards. Int J Nanomedicine.
3:133–149. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Farokhzad OC and Langer R: Impact of
nanotechnology on drug delivery. ACS Nano. 3:16–20. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kipp JE: The role of solid nanoparticle
technology in the parenteral delivery of poorly water-soluble
drugs. Int J Pharm. 284:109–122. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ahmad A, Sheikh S, Taran R, Srivastav SP,
Prasad K, Rajappa SJ, Kumar V, Gopichand M, Paithankar M, Sharma M,
et al: Therapeutic efficacy of a novel nanosomal docetaxel lipid
suspension compared with taxotere in locally advanced or metastatic
breast cancer patients. Clin Breast Cancer. 14:177–181. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Jong WH and Borm PJ: Drug delivery and
nanoparticles: Applications and hazards. Int J Nanomedicine.
3:133–149. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kipp JE: The role of solid nanoparticle
technology in the parenteral delivery of poorly water-soluble
drugs. Int J Pharm. 284:109–122. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kelly WK, Halabi S, Carducci M, George D,
Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, et
al: Randomized, double-blind, placebo-controlled phase III trial
comparing docetaxel and prednisone with or without bevacizumab in
men with metastatic castration-resistant prostate cancer: CALGB
90401. J Clin Oncol. 30:1534–1540. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Urquhart LM: Taxanes as a first-line
systemic treatment in metastatic breast cancer. Clin J Oncol Nurs.
17:(Suppl). S15–S21. 2013. View Article : Google Scholar
|
|
23
|
Norris LB, Qureshi ZP, Bookstaver PB,
Raisch DW, Sartor O, Chen H, Chen F and Bennett CL: Polysorbate 80
hypersensitivity reactions: A renewed call to action. Commun Oncol.
7:425–428. 2010. View Article : Google Scholar
|
|
24
|
Yoo KE, Kang RY, Lee JY, Lee YJ, Suh SY,
Kim KS, Kim HS, Lee SH and Lee BK: Awareness of the adverse effects
associated with prophylactic corticosteroid use during docetaxel
therapy. Support Care Cancer. 23:1969–1977. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sparano JA, Makhson AN, Semiglazov VF,
Tjulandin SA, Balashova OI, Bondarenko IN, Bogdanova NV, Manikhas
GM, Oliynychenko GP, Chatikhine VA, et al: Pegylated liposomal
doxorubicin plus docetaxel significantly improves time to
progression without additive cardiotoxicity compared with docetaxel
monotherapy in patients with advanced breast cancer previously
treated with neoadjuvant-adjuvant anthracycline therapy: Results
from a randomized phase III study. J Clin Oncol. 27:4522–4529.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karlsson CT, Wiklund F, Grönberg H, Bergh
A and Melin B: Risk of prostate cancer after trans urethral
resection of BPH: A cohort and nested case-control study. Cancers
(Basel). 3:4127–4138. 2011. View Article : Google Scholar : PubMed/NCBI
|
